The latest market intelligence, insights and interviews covering the cell and gene therapy industry's most pressing challenges, from translation to automation, manufacturing to market access, viral vectors to bioreactors.
In this interview, Georgi Makin spoke with Beth San Segundo, President and CEO of OriGen, about collaborating with cell therapy customers to identify and customize single-use solutions for cryopreservation.
A recent interactive panel discussion explored a few key priority areas for early stage biotechs to consider in order to build a successful cell and gene therapy manufacturing pipeline. Here, I summarise key advice shared by the experts.
